Healthcare and drug companies are moving quickly to weave artificial intelligence into how they discover medicines and treat patients, according to a cluster of recent industry reports.
On the drug-development side, Genetic Engineering and Biotechnology News reports that pharmaceutical companies are racing to scale up AI as billions of dollars flow into drug discovery. The financing mood is optimistic elsewhere too: BioPharma Dive reports that gene-editing developer Scribe, a California drugmaker with collaborations already in place with Biogen, Sanofi and Eli Lilly, is plotting an IPO and could become the 14th biotech to go public in 2026.
The geography of biotech is shifting as well. BioPharma Dive reports that as Greater Boston's biotech industry sheds jobs, three less-expected regions are staking their own claims as up-and-coming hubs.
In the clinic and back office, AI is being rolled out in new ways. Fierce Healthcare reports that Commure has launched an AI-powered referral and patient intake platform, and that Akido Labs has brought on a new head of engineering to apply consumer product thinking to healthcare delivery. Local outlet 10TV reports that hospitals in central Ohio are changing how they care for patients using AI.
With adoption comes scrutiny. Healthcare IT News reports that Mayo Clinic has built processes to vet its AI algorithms for safety before they reach patients.
Why it matters: AI is no longer a side experiment in medicine — it is shaping where investment flows, which companies go public, and how patients are diagnosed and treated, making questions of safety and oversight increasingly urgent.